There are currently 1241 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
NCT05433142
Recruiting
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Sarah Cannon Research Institute, LLC, Nashville, Tennessee
Conditions: Clear Cell Renal Cell Carcinoma
Register for Updates
ADVENT Post Approval Study
NCT06431815
Recruiting
The ADVENT Post Approval Study (PAS) is a prospective, global, multicenter, observational study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245
Recruiting
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Tennessee Oncology - Nashville - Centennial Center for Blood Cancers Clinic, Nashville, Tennessee +7 locations
Conditions: Patients With Non-Small Cell Lung Cancer
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/28/2025
Locations: Akero Clinical Study Site, Nashville, Tennessee
Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Register for Updates
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06799000
Recruiting
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/28/2025
Locations: Advanced Research Experts, Nashville, Tennessee
Conditions: Hidradenitis Suppurativa
Register for Updates
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
NCT06974734
Recruiting
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies. This study is seeking participants who: * have advanced or metastatic non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, or pancreatic ductal adenocarcinoma (PDAC); * are able to provide tumor tissue samples; * have measurable disease. All participants will receive while at the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Sarah Cannon Research Institute - Pharmacy, Nashville, Tennessee +2 locations
Conditions: Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Register for Updates
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
NCT06496178
Recruiting
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Site 59, Nashville, Tennessee +1 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775
Recruiting
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, HER2-Positive Advanced Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
07/28/2025
Locations: Local Institution - 0363, Nashville, Tennessee +1 locations
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
NCT06517641
Recruiting
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
Gender:
ALL
Ages:
Between 3 years and 75 years
Trial Updated:
07/28/2025
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Severe Aplastic Anemia
Register for Updates
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235
Recruiting
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Urology Associates, P.C., Nashville, Tennessee +1 locations
Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Register for Updates
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362
Recruiting
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Gender:
ALL
Ages:
Between 40 years and 84 years
Trial Updated:
07/28/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Heart Failure
Register for Updates